Clinical and Translational Science Q1 Unclaimed
Clinical and Translational Science is a journal indexed in SJR in Medicine (miscellaneous) and Biochemistry, Genetics and Molecular Biology (miscellaneous) with an H index of 60. It is an CC BY-NC-ND Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on translational medicine, precision medicine, translational studies, quantitative pharmacology. It has an SJR impact factor of 1,109 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,109.
Type: Journal
Type of Copyright: CC BY-NC-ND
Languages: English
Open Access Policy: Open Access
Type of publications:
Publication frecuency: -



2700 €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
1,109
SJR Impact factor60
H Index239
Total Docs (Last Year)686
Total Docs (3 years)8534
Total Refs2489
Total Cites (3 years)647
Citable Docs (3 years)3.48
Cites/Doc (2 years)35.71
Ref/DocOther journals with similar parameters
Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1
Compare this journals
Aims and Scope
Best articles by citations
Building Capacity Across the Spectrum of Research Translation: Centers of Excellence within the Rochester Clinical and Translational Science Institute
View moreUsing Research Metrics to Improve Timelines: Proceedings from the 2nd Annual CTSA Clinical Research Management Workshop
View moreEffect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure
View moreA Data-Rich Recruitment Core to Support Translational Clinical Research
View moreImpact of Professional Student Mentored Research Fellowship on Medical Education and Academic Medicine Career Path
View moreMetabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate
View moreEvaluating and Giving Feedback to Mentors: New Evidence-Based Approaches
View moreTranslating Minimally Invasive Glaucoma Surgery Devices
View moreThe Bayh-Dole Act, A Lion without Claws
View moreEvaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
View morePublic Interest in Medical Research Participation: Does It Matter if Patients or Community Members Have Helped Design the Study?
View moreAre Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
View moreIn the NEWS A ROUNDUP OF NEWS AND INFORMATION FROM OUR COMMUNITY
View moreThe
View moreClinical Data: Sources and Types, Regulatory Constraints, Applications
View moreTranscriptional Regulation of beta2-Microglobulin Demonstrated Via a Novel Genomic and Proteomic Analysis of Percutaneously Collected Peripheral Atheroma
View moreThe Harvard Catalyst Common Reciprocal IRB Reliance Agreement: An Innovative Approach to Multisite IRB Review and Oversight
View moreIncreasing Diversity of the Biomedical Workforce through Community Engagement: The University of Utah Native American Summer Research Internship
View morePivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
View moreMoving from the Laboratory Bench to Patients' Bedside: Considerations for Effective Therapy with Stem Cells
View moreIsosorbide Dinitrate and Hydralazine as Therapy for African Americans with Heart Failure;a Failed Paradigm?
View moreImproving the Proficiency of Research Consent Administrators
View moreCTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes
View moreCYP2C9
View more
Comments